AACP
PTCT icon

Advantage Alpha Capital Partners’s PTC Therapeutics PTCT Stock Holding History

Advantage Alpha Capital Partners’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-3,595
Closed -$221K – 88
2025
Q3 		$221K Sell
3,595
-579
-14% -$30.2K 0.07% 126
2025
Q2 		$204K Buy
+4,174
New +$198K 0.06% 117

Other funds holding PTCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Advantage Alpha Capital Partners's PTCT Position: Q4 2025 in Review

Advantage Alpha Capital Partners sold out of PTC Therapeutics (PTCT) in Q4 2025, closing a stake of 3,595 shares — an estimated $221K sold.

Advantage Alpha Capital Partners first reported a position in PTCT in Q2 2025 and held it in 2 quarters. The position peaked at $221K in Q3 2025. 352 funds tracked by Wall St. Rank hold PTCT as of Q4 2025.

  • Advantage Alpha Capital Partners reported no remaining PTC Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Advantage Alpha Capital Partners sold 3,595 PTC Therapeutics shares in Q4 2025, an estimated $221K.
  • Advantage Alpha Capital Partners first reported a position in PTC Therapeutics in Q2 2025 and held it in 2 quarters.
  • Advantage Alpha Capital Partners's PTC Therapeutics position peaked at $221K in Q3 2025.
  • 352 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2025.

Based on Advantage Alpha Capital Partners's 13F filing for Q4 2025.